Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease
Authors:
- John-Charles A. LooJLJohn-Charles A. Loo
- 1 March 2009
- journal article
- clinical trial
- Published by Elsevier in Genetics in Medicine
- Vol. 11 (3) , 210-219
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Differential muscular glycogen clearance after enzyme replacement therapy in a mouse model of Pompe diseaseMolecular Genetics and Metabolism, 2007
- Chinese hamster ovary cell-derived recombinant human acid α-glucosidase in infantile-onset Pompe diseaseThe Journal of Pediatrics, 2006
- Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trialNeuromuscular Disorders, 2005
- Pediatric physical functioning reference curvesPediatric Neurology, 2004
- Long-Term Intravenous Treatment of Pompe Disease With Recombinant Human α-Glucosidase From MilkPediatrics, 2004
- Pompe disease in infants and childrenThe Journal of Pediatrics, 2004
- The Natural Course of Infantile Pompe’s Disease: 20 Original Cases Compared With 133 Cases From the LiteraturePediatrics, 2003
- Development of a disease-specific disability instrument for Pompe diseasePediatric Rehabilitation, 2003
- Recombinant human acid ??-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I/II clinical trialGenetics in Medicine, 2001
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958